Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

48.51 USD

Average target price

56.28 USD

Spread / Average Target

+16.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-5.94%	98.32B
ELI LILLY AND COMPANY	+28.10%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.84%	356B
MERCK & CO., INC.	+14.71%	320B
ABBVIE INC.	+4.88%	286B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.77%	142B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-16 pm EDT			After market 04:37:38 pm
48.26 ^USD	-0.52%		48.35	+0.19%

Apr. 15	Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	MT
Apr. 15	Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	MT

Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	Apr. 12	MT
TORL BioTherapeutics LLC announced that it has received $158 million in funding from a group of investors	Apr. 09	CI
Bristol Myers: cancer treatment results	Apr. 09	CF
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	Apr. 09	MT
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	Apr. 08	CI
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta...	Apr. 08
Bristol Myers: new data on schizophrenia	Apr. 08	CF
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies	Apr. 06	RE
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	Apr. 05	MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	Apr. 05	DJ
Bristol Myers: FDA approves Abecma in multiple myeloma	Apr. 05	CF
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	Apr. 05	RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy	Apr. 05	RE
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	Apr. 05	CI
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	Apr. 04	MT
Standard BioTools Enters Into Multi-Year Medicine Research Engagement With Bristol-Myers Squibb	Apr. 04	MT
Bristol-Myers' Reblozyl Approved in EU as First-Line Treatment of Transfusion-Dependent Anemia	Apr. 03	MT
Bristol Myers: EU approval extended for Reblozyl	Apr. 03	CF
European Commission Expands Approval of Bristol Myers Squibb?S Reblozyl® (Luspatercept)	Apr. 02	CI
Obsidian Therapeutics, Inc. announced that it has received $160.5 million in funding from a group of investors	Apr. 02	CI
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint	Apr. 01	MT
Bristol-Myers Solicits Proxies from the Shareholders	Mar. 28	CI